HUP0401196A2 - Csípőbélbeni epesav-transzportot gátló hatású benzotiazepin- és benzotiadiazepin-származékok, előállításuk és az ezeket tartalmazó gyógyászati készítmények hiperlipidémia kezelésére - Google Patents
Csípőbélbeni epesav-transzportot gátló hatású benzotiazepin- és benzotiadiazepin-származékok, előállításuk és az ezeket tartalmazó gyógyászati készítmények hiperlipidémia kezeléséreInfo
- Publication number
- HUP0401196A2 HUP0401196A2 HU0401196A HUP0401196A HUP0401196A2 HU P0401196 A2 HUP0401196 A2 HU P0401196A2 HU 0401196 A HU0401196 A HU 0401196A HU P0401196 A HUP0401196 A HU P0401196A HU P0401196 A2 HUP0401196 A2 HU P0401196A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- amino
- group
- sulfamoyl
- carbamoyl
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 hydroxyl- Chemical group 0.000 abstract 20
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre, valamint azokgyógyászatilag alkalmazható sóira, szolvátjaira, a sók szolvátjaira éselőgyógyszer-származékaikra vonatkozik - a képletben Rv hidrogénatomotvagy 1-6 szénatomos alkilcsoportot jelent; R1 és R2 közül az egyikhidrogénatomot vagy 1-6 szénatomos alkil- vagy 2-6 szénatomosalkenilcsoportot, a másik pedig 1-6 szénatomos alkil- vagy 2-6szénatomos alkenilcsoportot jelent; Rx és Ry egymástól függetlenülhidrogénatomot vagy hidroxil-, amino-, merkapto-, 1-6 szénatomosalkil-, 1-6 szénatomos alkoxi-, N-(1-6 szénatomos alkil-amino-; N,N-di-(1-6 szénatomos alkil)-amino- vagy (1-6 szénatomos alkil)-S(O)a-csoportot jelent, ahol az utóbbiban a értéke 0-2; M -N- vagy -CH-csoportot jelent; Rz halogénatomot vagy nitro-, ciano-, hidroxil-,amino-, karboxil-, karbamoil-, merkapto-, szulfamoil-, 1-6 szénatomosalkil-, 2-6 szénatomos alkenil-, 2-6 szénatomos alkinil-, 1-6szénatomos alkoxi-, 1-6 szénatomos alkanoil-, 1-6 szénatomos alkanoil-oxi-, N-(1-6 szénatomos alkil)-amino-, N,N-di-(1-6 szénatomos alkil)-amino-, 1-6 szénatomos alkanoil-amino-, N-(1-6 szénatomos alkil)-karbamoil-, N,N-di-(1-6 szénatomos alkil)-karbamoil-, (1-6 szénatomosalkoxi)-karbonil-, N-(1-6 szénatomos alkil)-szulfamoil-, N,N-di-(1-6szénatomos alkil)-szulfamoil- vagy (1-6 szénatomos alkil)-S(O)a-csoportot jelent, ahol az utóbbiban a értéke 0-2; v értéke 0-5; R3 ésR6; továbbá R4 és R5 közül az egyik csoport egymástól függetlenülhidrogénatomot, halogénatomot vagy nitro-, ciano-, hidroxil-, amino-,karboxil-, karbamoil-, merkapto-, szulfamoil-, 1-4 szénatomos alkil-,2-4 szénatomos afkenil-, 2-4 szénatomos alkinil-, 1-4 szénatomosalkoxi-, 1-4 szénatomos alkanoil-, 1-4 szénatomos alkanoil-oxi-, N-(1-4 szénatomos alkil)-amino-, N,N-di-(1-4 szénatomos alkil)-amino-, 1-4szénatomos alkanoil-amino-, N-(1-4 szénatomos alkil)-karbamoil-, N,N-di-(1-4 szénatomos alkil)-karbamoil-, (1-4 szénatomos alkoxi)-karbonil-, N-(1-4 szénatomos alkil)-szulfamoil-, N,N-di-(1-4szénatomos alkil)-szulfamoil- vagy (1-4 szénatomos alkil)-S(O)a-csoportot jelent, ahol az utóbbiban a értéke 0-2; mimellett R3-hoz,R6-hoz, továbbá R4 és R5 közül az egyik csoporthoz adott esetbenszénatomon keresztül egy vagy több R16 szubsztituens kapcsolódhat; ésR4 és R5 közül a másik csoport (IA) általános képletű csoportotjelent. A találmány tárgya továbbá az (I) általános képletű vegyületekelőállítása és az (I) általános képletű vegyületeket tartalmazógyógyszerek. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0121768A GB0121768D0 (en) | 2001-09-08 | 2001-09-08 | Chemical compounds |
| GB0209463A GB0209463D0 (en) | 2002-04-25 | 2002-04-25 | Chemical compounds |
| PCT/GB2002/004033 WO2003022286A1 (en) | 2001-09-08 | 2002-09-05 | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0401196A2 true HUP0401196A2 (hu) | 2004-10-28 |
| HUP0401196A3 HUP0401196A3 (en) | 2008-01-28 |
| HU227623B1 HU227623B1 (en) | 2011-09-28 |
Family
ID=26246524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401196A HU227623B1 (en) | 2001-09-08 | 2002-09-05 | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia, process for their preparation and pharmaceutical compositions containing them |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7132416B2 (hu) |
| EP (1) | EP1427423B9 (hu) |
| JP (2) | JP3616635B2 (hu) |
| KR (1) | KR100935623B1 (hu) |
| CN (1) | CN1582151A (hu) |
| AR (1) | AR037089A1 (hu) |
| AT (1) | ATE349214T1 (hu) |
| AU (1) | AU2002329387B2 (hu) |
| BR (1) | BRPI0212346B1 (hu) |
| CA (1) | CA2459449C (hu) |
| CO (1) | CO5570671A2 (hu) |
| CY (1) | CY1106348T1 (hu) |
| DE (1) | DE60217136T2 (hu) |
| DK (1) | DK1427423T5 (hu) |
| ES (1) | ES2278045T3 (hu) |
| HK (1) | HK1065258A1 (hu) |
| HU (1) | HU227623B1 (hu) |
| IL (2) | IL160691A0 (hu) |
| IS (1) | IS7170A (hu) |
| MX (1) | MXPA04002179A (hu) |
| MY (1) | MY131995A (hu) |
| NO (1) | NO327041B1 (hu) |
| NZ (1) | NZ531796A (hu) |
| PL (1) | PL216023B1 (hu) |
| PT (1) | PT1427423E (hu) |
| RU (1) | RU2305681C2 (hu) |
| TW (1) | TWI331143B (hu) |
| UY (1) | UY27436A1 (hu) |
| WO (1) | WO2003022286A1 (hu) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) * | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) * | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| DK1517883T3 (da) | 2002-06-20 | 2008-05-26 | Astrazeneca Ab | Ortho-substituerede benzoesyrederivater til behandling af insulinresistens |
| GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
| GB0314131D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US7528448B2 (en) * | 2006-07-17 | 2009-05-05 | E.I. Du Pont De Nemours And Company | Thin film transistor comprising novel conductor and dielectric compositions |
| US8062824B2 (en) | 2006-07-17 | 2011-11-22 | E. I. Du Pont De Nemours And Company | Thermally imageable dielectric layers, thermal transfer donors and receivers |
| EP2125711B1 (en) * | 2007-03-08 | 2013-11-06 | Albireo Ab | 3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| US7666567B2 (en) | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Negative imaging method for providing a patterned metal layer having high conductivity |
| US7666568B2 (en) * | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Composition and method for providing a patterned metal layer having high conductivity |
| CN102316872B (zh) * | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| AU2011326871B2 (en) | 2010-11-08 | 2015-02-12 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| MY176863A (en) * | 2010-11-08 | 2020-08-24 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| US20120114588A1 (en) * | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| EA201891154A1 (ru) * | 2011-10-28 | 2019-02-28 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей |
| SG11201401816SA (en) | 2011-10-28 | 2014-05-29 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| MX2015013196A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| WO2017138877A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| CA3091338A1 (en) * | 2018-03-09 | 2019-09-12 | Elobix Ab | Process for the preparation of elobixibat |
| US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| TWI823954B (zh) | 2018-06-20 | 2023-12-01 | 瑞典商艾爾比瑞歐公司 | 奧德維希百(odevixibat)之結晶修飾物 |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| JP7504109B2 (ja) * | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| BR112021015809A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar |
| KR20220061110A (ko) * | 2019-09-09 | 2022-05-12 | 이에이 파마 가부시키가이샤 | 1,5-벤조티아제핀 화합물을 제조하기 위한 방법 |
| PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| MX2022006731A (es) * | 2019-12-04 | 2022-06-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar. |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
| WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
| AU2023255249A1 (en) | 2022-04-22 | 2024-10-17 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240173333A1 (en) | 2022-11-03 | 2024-05-30 | Albireo Ab | Treating Alagille Syndrome (ALGS) |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2024121431A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Cocrystals of odevixibat |
| WO2024184924A1 (en) * | 2023-03-06 | 2024-09-12 | Rk Pharma Inc | "an improved process for the preparation of odevixibat and its crystalline forms" |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| CN1110494C (zh) | 1996-03-11 | 2003-06-04 | G·D·瑟尔公司 | 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因 |
| GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| PL336415A1 (en) | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
| ES2198613T3 (es) | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
| AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
| WO1999032478A1 (en) | 1997-12-19 | 1999-07-01 | G.D. Searle & Co. | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JP2002533415A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ |
| EA200100707A1 (ru) | 1998-12-23 | 2001-12-24 | Джи.Ди.Сирл Ллс | Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний |
| BR9916484A (pt) | 1998-12-23 | 2002-01-22 | Searle Llc | Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares |
| CN1342089A (zh) | 1998-12-23 | 2002-03-27 | G.D.瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆固醇酯转移蛋白抑制剂的组合 |
| EP1140187B1 (en) | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications |
| EP1155007A2 (en) | 1999-02-12 | 2001-11-21 | G.D. Searle LLC | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US6794544B2 (en) | 2000-03-10 | 2004-09-21 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| AU2001247331A1 (en) | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
-
2002
- 2002-09-05 TW TW091120297A patent/TWI331143B/zh not_active IP Right Cessation
- 2002-09-05 RU RU2004110716/04A patent/RU2305681C2/ru active
- 2002-09-05 DK DK02765013.4T patent/DK1427423T5/da active
- 2002-09-05 HU HU0401196A patent/HU227623B1/hu unknown
- 2002-09-05 CA CA2459449A patent/CA2459449C/en not_active Expired - Lifetime
- 2002-09-05 IL IL16069102A patent/IL160691A0/xx unknown
- 2002-09-05 AT AT02765013T patent/ATE349214T1/de active
- 2002-09-05 DE DE60217136T patent/DE60217136T2/de not_active Expired - Lifetime
- 2002-09-05 MY MYPI20023317A patent/MY131995A/en unknown
- 2002-09-05 AU AU2002329387A patent/AU2002329387B2/en not_active Expired
- 2002-09-05 ES ES02765013T patent/ES2278045T3/es not_active Expired - Lifetime
- 2002-09-05 KR KR1020047003407A patent/KR100935623B1/ko active IP Right Grant
- 2002-09-05 PT PT02765013T patent/PT1427423E/pt unknown
- 2002-09-05 MX MXPA04002179A patent/MXPA04002179A/es active IP Right Grant
- 2002-09-05 NZ NZ531796A patent/NZ531796A/en not_active IP Right Cessation
- 2002-09-05 US US10/488,870 patent/US7132416B2/en not_active Expired - Lifetime
- 2002-09-05 EP EP02765013.4A patent/EP1427423B9/en not_active Expired - Lifetime
- 2002-09-05 BR BRPI0212346A patent/BRPI0212346B1/pt not_active IP Right Cessation
- 2002-09-05 PL PL369078A patent/PL216023B1/pl unknown
- 2002-09-05 WO PCT/GB2002/004033 patent/WO2003022286A1/en active IP Right Grant
- 2002-09-05 CN CNA028221133A patent/CN1582151A/zh active Pending
- 2002-09-05 JP JP2003526415A patent/JP3616635B2/ja not_active Expired - Lifetime
- 2002-09-06 UY UY27436A patent/UY27436A1/es not_active IP Right Cessation
- 2002-09-06 AR ARP020103379A patent/AR037089A1/es active IP Right Grant
-
2004
- 2004-02-16 JP JP2004038919A patent/JP2004210794A/ja active Pending
- 2004-03-02 IL IL160691A patent/IL160691A/en active IP Right Grant
- 2004-03-04 IS IS7170A patent/IS7170A/is unknown
- 2004-03-04 NO NO20040948A patent/NO327041B1/no not_active IP Right Cessation
- 2004-04-06 CO CO04032561A patent/CO5570671A2/es not_active Application Discontinuation
- 2004-10-18 HK HK04108119A patent/HK1065258A1/xx not_active IP Right Cessation
-
2007
- 2007-03-01 CY CY20071100289T patent/CY1106348T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401196A2 (hu) | Csípőbélbeni epesav-transzportot gátló hatású benzotiazepin- és benzotiadiazepin-származékok, előállításuk és az ezeket tartalmazó gyógyászati készítmények hiperlipidémia kezelésére | |
| WO2003091232A3 (en) | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| HUP0301953A2 (hu) | 1,5-Benzotiazepinek, eljárás előállításukra és felhasználásuk hiperlipidémia-ellenes szerekként | |
| HUP0302922A2 (hu) | Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0102840A2 (hu) | Epesav transzportot és taurokolát felvételt gátló benzotiepinszármazékok, valamint ezeket tartalmazó gyógyászati készítmények és eljárás a hatóanyagok előállítására | |
| HUP0401855A2 (hu) | Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0303347A2 (hu) | (R)-2-aril-propionsav-omega-aminoalkilamidok mint polimorf magvú és egymagvú sejtek kemotaxisának inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| AU3755601A (en) | 1,5-benzothiazepines and their use as hypolipidaemics | |
| IL160690A0 (en) | Benzothiazepine ileal bile acid transport inhibitors | |
| HUP0102554A1 (hu) | Benzotiepin-1,1-dioxid-származékok, ezek előállítására szolgáló eljárás, ezeket tartalmazó gyógyszerek és ezek alkalmazása | |
| HUP0300080A2 (hu) | Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények | |
| MY134270A (en) | Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions | |
| HUP0300416A2 (hu) | Antibiotikus hatású oxazolidinon-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0102723A2 (hu) | Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
| HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DE3876813D1 (de) | 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a. | |
| WO2003082861A3 (en) | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases | |
| HUP0102599A2 (hu) | Artemizinin-származékok, eljárás a vegyületek előállítására, és a vegyületeket tartalmazó gyógyszerészeti készítmények | |
| HUP0102031A2 (hu) | Széles spektrumú gombásodásgátló hatású vízoldható azolok, eljárás az előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| EP1342720A3 (en) | Epoxysuccinamide derivatives | |
| EP1671957A4 (en) | THIADIAZOLINDERIVATE | |
| HUP0105116A2 (hu) | 2,3-0-Izopropilidén-monoszacharid-származékok, mint sejtadhézió-gátlók és az ezeket tartalmazó gyógyászati készítmények, eljárás a vegyületek előállítására | |
| HUP0004317A2 (hu) | 5-HT1F agonisták | |
| AU3285000A (en) | 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: ALBIREO AB, SE Free format text: FORMER OWNER(S): ASTRAZENECA AB,, SE |